The Cochrane database of systematic reviews

Starting calcium supplements before or early in pregnancy to help prevent pregnancy-related high blood pressure

Updated

Abstract

Calcium supplementation before or early in pregnancy may make little or no difference to the risk of pre-eclampsia, with inconclusive results for various maternal and fetal outcomes.

  • A single study involving 1355 women indicated that calcium supplementation starting before conception may not significantly affect the risk of pre-eclampsia.
  • The composite outcome of pre-eclampsia or pregnancy loss may be slightly reduced by calcium, but the evidence is considered low quality.
  • Calcium supplementation showed little or no effect on severe maternal morbidity and mortality, pregnancy loss, or caesarean section rates.
  • There was no clear evidence of calcium's impact on birthweight, preterm birth, or neonatal outcomes.
  • The current evidence does not support or refute routine calcium supplementation before conception and in early pregnancy.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Justus Hofmeyr is author of one study included in the review and did not participate in decisions regarding this study (Hofmeyr 2019). Two of the other review authors, who are not directly involved with the trial, evaluated the trial for inclusion, assessed risk of bias, and carried out data extraction and GRADE assessments. Alternative Discovery & Development, GlaxoSmithKline (GSK) Medicines Research Centre, UK, partnered with the same study to collect blood samples from a sub‐group of participants in the trial for an independent, open‐innovation pre‐eclampsia biomarker study, following a separate protocol, which was approved by the trial ethics committee. Apart from direct funding to the largest site (Chris Hani Baragwanath Hospital) specifically for the costs of this blood sample collection, GSK provided no funding to the main trial, and did not participate in any aspect of the main trial. Sarah Manyame is an investigator on Hofmeyr 2019; however, she was not involved in any decisions relating to the trial. Two of the other review authors, who are not directly involved with the trial, evaluated the trial for inclusion, assessed risk of bias, and carried out data extraction and GRADE assessments. Alternative Discovery & Development, GlaxoSmithKline (GSK) Medicines Research Centre, UK, partnered with the same study to collect blood samples from a sub‐group of participants in the trial for an independent, open‐innovation pre‐eclampsia biomarker study, following a separate protocol, which was approved by the trial ethics committee. Apart from direct funding to the largest site (Chris Hani Baragwanath Hospital) specifically for the costs of this blood sample collection, GSK provided no funding to the main trial, and did not participate in any aspect of the main trial. Nancy Medley's contribution to this review was financially supported by the World Health Organization. Myfanwy J Williams is employed by the University of Liverpool as a Research Associate for Cochrane Pregnancy and Childbirth. Her role is supported by the World Health Organization.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free